Webinar to be Hosted on October 6 at 4:00 p.m. ET; Register Here

NEW YORK, Sept. 8, 2026 /PRNewswire/ -- Bluerock Private Real Estate Fund (ticker: BPRE, the "Fund") today announced that its next semi-annual BPRE Strategic Roadmap progress report webinar is scheduled for October 6, 2026, at 4pm ET.

The webinar, "BPRE Strategic Roadmap: A Progress Report", will feature Ryan MacDonald, Chief Investment Officer, and Steven Baffico, Head of Listed Products, who will review BPRE's progress in executing on the Fund's previously announced strategic roadmap to maximize shareholder value. The plan focuses on two primary pillars: rotating capital out of BPRE's legacy core+ institutional fund holdings into the specialty direct real estate investments it believes offer stronger total return potential, and consistently raising distributions.

"We are moving decisively to execute on the roadmap we have laid out for shareholders with the goal of maximizing value in BPRE," said Mr. MacDonald. "Capital rotation into our target high-growth sectors is well underway, and we look forward to walking investors through the real estate deals we have committed capital to, as well as the pipeline taking shape in the months to come."

BPRE has announced four distribution increases since listing, raising the Fund's distribution on NAV from 5.25% at listing in December 2025 to 7.0% in June 2026,1 reflecting management's commitment to consistently raising distributions as it executes on its strategic plan.

Institutional and retail shareholders, along with financial professionals, may register for the webinar at go.bluerock.com/bh0BI2 or at www.bprefund.com. BPRE's May 2026 progress report presentation and highlights video may also be found at the Fund's website.

Some or all of the Fund's distributions may be deemed to be a return of capital. The Fund provides a notice of its best estimate of the sources of a distribution at the time of such distribution. Such notice and other detailed Fund information is available at bprefund.com.

Bluerock Private Real Estate Fund (ticker: BPRE) is the only New York Stock Exchange-listed closed-end fund offering investors dedicated access to private real estate. The Fund is the largest real estate-focused closed-end fund on the market and is designed to deliver strong, consistent tax-advantaged income while also pursuing attractive long-term capital appreciation. Following its December 2025 listing, BPRE has been executing on its strategic roadmap plan to maximize shareholder value by rotating capital into high-growth, specialty real estate sectors and consistently raising distributions, having announced four distribution increases since listing. Learn more about BPRE at bprefund.com.

1 Rates calculated by annualizing monthly distributions divided by the ex-date NAV of each month.

IMPORTANT INFORMATION ON RISK

Investing in the Fund involves risks, including the risk that you may receive little or no return on your investment or that you may lose part or all of your investment. Investors should carefully consider the investment objectives, risks, charges, and expenses of BPRE, as detailed in BPRE's shelf registration statement on Form N-2 filed with the SEC.

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

Statements included herein may constitute "forward-looking" statements as that term is defined in Section 27A of the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995, including statements with regard to future events or the future performance or operations of the Fund, including but not limited to, liquidity events. Words such as "intends," "will," "believes," "expects," and "may" or similar expressions are intended to identify forward-looking statements. These forward-looking statements are subject to the inherent uncertainties in predicting future results and conditions. Certain factors could cause actual results to differ materially from those projected in these forward-looking statements. Factors that could cause actual results to differ materially include changes in the economy, geo-political risks, risks associated with possible disruption to the Fund's operations or the economy generally due to hostilities, terrorism, natural disasters or pandemics such as COVID-19, future changes in laws or regulations and conditions in the Fund's operating area, unexpected costs, the ability of the Fund to complete the listing of the common shares on a national securities exchange, the price at which the common shares may trade on a national securities exchange, and failure to list the common shares on a national securities exchange, and such other factors that are disclosed in the Fund's filings with the Securities and Exchange Commission (the "SEC"). The inclusion of forward-looking statements should not be regarded as a representation that any plans, estimates or expectations will be achieved. Any forward-looking statements speak only as of the date of this communication. Except as required by federal securities laws, the Fund undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Readers are cautioned not to place undue reliance on any of these forward-looking statements.

NO OFFER OR SOLICITATION

The information contained in this communication is for informational purposes only. The foregoing is not intended to be an offering of securities, nor does it constitute an offer to purchase, or a solicitation of an offer to sell, subscribe for, or buy any securities in any jurisdiction. Anyone interested in investing in the Company is directed exclusively to the materials and periodic reports filed by the Company with the Securities and Exchange Commission (SEC).

SOURCE Bluerock Private Real Estate Fund

Share this article

The free global virtual event returns with expanded programming, new continuing education opportunities, and $5,000 scholarships for nurses worldwide. Registration is now open.

CINCINNATI, Sept. 8, 2026 /PRNewswire/ -- As nurses navigate an increasingly complex profession, questions about what comes next in their careers have never mattered more. This November, Nursing Careers Week returns to help nurses find answers—and new possibilities.

Created by Health Carousel, Nursing Careers Week 2026 will take place November 9–13, bringing nurses around the world together for five days of free virtual programming focused on career growth, connection, resilience, and opportunity. From students and bedside nurses to international nurses, educators, travel nurses, and nurse leaders, the event is designed to help nurses take greater ownership of where their careers can go next.

Now in its third year, Nursing Careers Week was created to address a gap that has long challenged the profession: access to career development resources and opportunities hasn't kept pace with the growing demands placed on nurses. What began as a commitment to change has grown into a global movement, reaching nurses from across the United States and more than 45 countries in its second year.

Building on more than 15,000 registrations, 20+ partner organizations, and thousands of dollars awarded in scholarships and giveaways, the 2026 event will offer a more curated, high-impact experience organized around three programming tracks — The Empowered Nurse, The Resilient Nurse, and The Global Nurse — covering everything from leadership and entrepreneurship to well-being, financial wellness, and international career pathways for nurses both pursuing opportunities abroad and strengthening care in their home countries.

"Nursing Careers Week was a light in the middle of so much uncertainty. Before that week, my career path felt unclear and I often felt like I was navigating it alone. After attending, everything shifted. I realized there were more possibilities ahead of me than I had ever allowed myself to imagine — and that there was an entire global community of nurses walking alongside me." — 2025 Nursing Careers Week Attendee

New for 2026, Learn and Earn Day gives nurses a dedicated day to earn continuing education credits through free, self-paced accredited webinars — a first for the event. Registered attendees will also be eligible for $5,000 scholarships and daily $250 giveaways throughout the week.

"What nurses are telling us — loudly and clearly — is that they want more than a job. They want a career with purpose, flexibility, and a future they can actually see themselves in," said Earl Dalton, MHA, MSL, RN, NEA-BC, FAAN, Chief Clinical Officer and Vice President of Clinical Services at Health Carousel. "Every nurse — regardless of where they are in the world or where they stand in their career — deserves access to the resources and community that can truly change their trajectory. We are proud to bring that back for a third year and make it the most impactful experience we have ever delivered."

Nursing Careers Week is supported by a growing coalition of healthcare organizations, nursing associations, educational institutions, and advocacy groups united by a shared commitment to advancing the profession globally.

Among this year's partners is Shannon McPeek, BSN, RN, Founder and CEO of Operation Happy Nurse, a nonprofit dedicated to supporting nurses facing stress, anxiety, and depression.

"Nursing is equal parts rewarding and extremely difficult. While we, as healthcare workers, continue to acknowledge the difficulties of the profession, some organizations don't. We partner with Nursing Careers Week because they do. They provide adequate resources for nurses to celebrate the rewarding parts of the profession while simultaneously acknowledging the difficult ones. They share the voices of nurses and give our community space to share resources and support each other. Nursing Careers Week helps support the real work of nursing, McPeek said."

Full event details, session previews, and registration information are available at NursingCareersWeek.com.

About Health Carousel

Health Carousel is a leading healthcare workforce solutions company committed to improving lives and advancing the nursing profession worldwide. Through its family of brands, Health Carousel connects healthcare professionals and organizations across the globe, delivering staffing, workforce management, and career development solutions that strengthen healthcare systems and support the nurses who power them. For more information on Health Carousel, visit www.HealthCarousel.com.

Media Contact:

Lindsay Koehl, Director, Nursing Careers Week, Health Carousel, [email protected]

SOURCE Health Carousel

Share this article

Former Air Force Futures senior leader brings nearly three decades of operational, strategic, and capability development experience to CoAspire.

FAIRFAX, Va., Sept. 8, 2026 /PRNewswire/ -- CoAspire (www.coaspire.com) announced today that Brigadier General (Ret.) Jason L. Hawk has joined the company as an Executive Vice President, bringing nearly three decades of military leadership and extensive experience in future force design, advanced weapons and technology, strategic planning, and large-scale operations.

Hawk retired from the U.S. Air Force in August 2025 following a career that culminated at the Pentagon as Deputy Director, Capability Development, Air Force Futures, Headquarters U.S. Air Force. In that role, he led Air Force capability development and Joint integration, shaping operational requirements and investment priorities across three consecutive programming cycles representing approximately $200 billion in RDT&E and procurement.

His portfolio spanned the full range of Air Force capabilities, including next-generation airpower, weapons and sensors, autonomous systems and artificial intelligence, command and control, space and cyber, base defense, and mobility. Hawk was involved in capability development and modernization efforts supporting programs including Next Generation Air Dominance, Collaborative Combat Aircraft, C3BM, and B-21.

"Jason's experience sits directly at the intersection of where CoAspire is today and where we are going," said Doug Denneny, Founder and CEO of CoAspire. "He understands the warfighter, how the Department develops requirements and prioritizes capabilities, and what it takes to move technology from an idea to an operational solution. Jason has led at every level, from the cockpit to the Pentagon, and we're thrilled to have him join our senior leadership team."

Prior to Air Force Futures, Hawk served in senior leadership positions at the National Guard Bureau. As a Deputy Director for Air, Intelligence and Cyber Operations, he oversaw readiness, mobilization, and current operations for the Air National Guard — approximately 107,000 Airmen, 90 wings, and 1,200 aircraft, supported by an approximately $11 billion annual operating budget.

Hawk commanded at the squadron and group levels and served for more than two decades as an operational aviator. He began his aviation career in the U.S. Army flying the AH-64 Apache before transitioning to the Air Force and the F-16 Fighting Falcon. A Command Pilot, instructor, and evaluator, Hawk accumulated more than 1,700 flight hours in fighter and attack aircraft and flew operational missions supporting NATO, homeland defense, and U.S. Indo-Pacific Command requirements.

"I've spent my career focused on understanding how to simplify complex defense systems, and how we get the capabilities our warfighters need into their hands faster," Hawk said. "CoAspire has demonstrated that a small, innovative company can challenge traditional timelines and rapidly turn requirements into fieldable capability. I'm excited to join Doug and the senior leadership team as we scale the company and continue delivering affordable capability at speed and scale for the United States and our allies."

Hawk holds an MBA from the University of Virginia Darden School of Business, a Master of Strategic Studies from the U.S. Army War College, and a Master of Science in Aviation Operations from Embry-Riddle Aeronautical University. His executive education includes programs at the Harvard Kennedy School and UNC Kenan-Flagler Business School.

About CoAspire

Founded in 2013, CoAspire (www.coaspire.com) is a Virginia-based defense company and prime contractor developing and producing affordable mass cruise missiles and other capabilities for the U.S. Department of War and allied nations. CoAspire is the developer of the Rapidly Adaptable Affordable Cruise Missile (RAACM) family of weapons and is focused on rapidly delivering affordable, scalable capabilities to meet emerging national security requirements.

SOURCE CoAspire

Share this article

PeproMene Bio anuncia la publicación en The Lancet de los resultados de su ensayo clínico de fase 1

News provided by

PeproMene Bio, Inc.; Institute for Follicular Lymphoma Innovation (IFLI)

Sep 08, 2026, 06:01 ET

-PeproMene Bio anuncia la publicación en The Lancet de los resultados de un innovador ensayo clínico de fase 1 que demuestra respuestas completas profundas y duraderas en linfomas de células B de recaída/refractarios, incluso después de un fracaso previo del tratamiento con células T CD19 CAR

IRVINE, Calif., 8 de septiembre de 2026 /PRNewswire/ -- PeproMene Bio, Inc. Anunció hoy la publicación en The Lancet, una de las principales revistas médicas del mundo, de los resultados de su ensayo clínico de Fase 1 que evalúa PMB-CT01, la primera terapia de células T CAR dirigida a BAFF-R de la compañía, en pacientes con linfoma no Hodgkin de células B de recaída o refractario.

La publicación informa de respuestas clínicas completas y duraderas, junto con un perfil de seguridad más favorable en comparación con las terapias de células T CAR aprobadas. Siete de los nueve pacientes tratados (80 %) lograron una respuesta completa (RC), incluyendo cuatro de los seis pacientes que habían progresado tras la terapia convencional de células T CAR dirigidas a CD19 ("CAR después de CAR"). Todas las respuestas completas se mantenían vigentes en el momento del corte de datos, sin observarse recaídas y con la respuesta completa más prolongada alcanzando los 35 meses, lo que sugiere la probabilidad de curación.

PMB-CT01 demostró una seguridad notable, ya que todos los eventos de síndrome de liberación de citoquinas (CRS) y los dos eventos de síndrome de neurotoxicidad asociado a células efectoras inmunitarias (ICANS) notificados se limitaron al grado 1.

Basándose en estos prometedores resultados, el ensayo de fase 1 se ha expandido desde un único centro clínico en City of Hope, una organización de investigación y tratamiento del cáncer, a múltiples centros médicos adicionales en todo Estados Unidos. La publicación también informa que el primer paciente tratado en la fase de expansión —que padecía linfoma de células B de alto grado con triple mutación tras la progresión de la enfermedad con terapia de células T CAR dirigidas a CD19— también logró una respuesta completa en la primera evaluación de la enfermedad.

"La publicación de estos datos revisados por pares en The Lancet representa un reconocimiento significativo de esta novedosa terapia", afirmó Larry W. Kwak, M.D., Ph.D., fundador científico de PeproMene Bio. "Ante la ausencia de recaídas, creemos que PMB-CT01 es una opción de terapia de células T CAR revolucionaria para los cánceres de la sangre que antes se consideraban incurables. Su seguridad excepcional también podría permitir la administración ambulatoria, mejorando el acceso para pacientes con recursos limitados, y abriendo nuevas posibilidades para el tratamiento de enfermedades autoinmunes en las que la depleción de células B ya ha demostrado su eficacia".

"Estos primeros resultados son alentadores, especialmente para los pacientes cuya enfermedad progresó tras la terapia con células T dirigidas a CD19 o CD20", afirmó el Dr. Stephen Forman, coautor del artículo y director del Instituto de Neoplasias Hematológicas de City of Hope. "City of Hope seguirá apoyando el ensayo como centro coordinador y planta de fabricación, además de la captación de pacientes".

En diciembre de 2024, el Instituto para la Innovación en Linfoma Folicular (IFLI) se comprometió a aportar hasta 11 millones de dólares para apoyar el desarrollo clínico de PMB-CT01 en pacientes con linfoma folicular recidivante o refractario. "Para los pacientes cuyo linfoma reaparece tras la terapia con células T CAR dirigidas a CD19, un nuevo objetivo terapéutico puede suponer una nueva oportunidad. El IFLI se enorgullece de apoyar a PeproMene Bio en el avance de la terapia con células T CAR BAFF-R y se siente alentado por estas respuestas tempranas y duraderas", declaró Mehrdad Mobasher, M.D., M.P.H., socio ejecutivo del Instituto para la Innovación en Linfoma Folicular.

Detalles de la publicación

Título: BAFF-R CAR T-cell therapy for relapsed or refractory B-cell lymphomas

Revista: The Lancet (Research Letter)

DOI: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)01329-2/fulltext

Acerca de PMB-CT01

PMB-CT01 es una terapia de células T CAR autólogas dirigida al receptor del factor activador de células B (BAFF-R), la primera de su clase, que se está evaluando en ensayos de fase 1 en curso para linfoma no Hodgkin de células B de recaída/refractario y leucemia linfoblástica aguda de células B de recaída/refractaria. BAFF-R se expresa casi exclusivamente en las células B y es esencial para su supervivencia, reduciendo la probabilidad de escape por pérdida de antígeno. PeproMene Bio ha obtenido la licencia de la propiedad intelectual relacionada con PMB-CT01 de City of Hope.

Acerca de PeproMene Bio

PeproMene Bio, Inc. es una empresa de biotecnología en fase clínica con sede en Irvine, California, que desarrolla terapias innovadoras para el tratamiento del cáncer y los trastornos inmunitarios. Para obtener más información, póngase en contacto con Hazel Cheng, Ph.D., directora de operaciones de PeproMene Bio, Inc. en [email protected] o visite https://pepromenebio.com/.

Declaraciones prospectivas

Este comunicado de prensa contiene declaraciones prospectivas sujetas a riesgos e incertidumbres, incluidos los riesgos relacionados con el desarrollo clínico, los resultados regulatorios, el potencial terapéutico y la comercialización. PeproMene Bio no asume ninguna obligación de actualizar las declaraciones prospectivas, salvo que lo exija la ley.

Contacto para medios, IFLI

Laura DiCaprio, APR

McDougall Communications

[email protected]

Share this article

PeproMene Bio annonce la publication dans The Lancet des résultats d'un essai clinique de phase 1 démontrant des réponses complètes profondes et durables dans les lymphomes à cellules B récidivants ou réfractaires, y compris après l'échec d'un traitement par cellules CAR-T ciblant le CD19

News provided by

PeproMene Bio, Inc.; Institute for Follicular Lymphoma Innovation (IFLI)

Sep 08, 2026, 06:01 ET

IRVINE, Californie, 8 septembre 2026 /PRNewswire/ -- PeproMene Bio, Inc. annonce ce jour la publication dans The Lancet, l'une des revues médicales les plus prestigieuses au monde, des résultats de son essai clinique de phase 1 évaluant le PMB-CT01, une thérapie pionnière à base de cellules CAR-T ciblant le BAFF-R, chez des patients atteints d'un lymphome non hodgkinien à cellules B récidivant ou réfractaire.

Cette étude fait état de réponses cliniques complètes et durables, ainsi que d'un profil d'innocuité plus favorable que celui des thérapies à base de cellules CAR-T déjà autorisées. Sept des neuf patients traités (80 %) ont obtenu une réponse complète (RC), dont quatre des six patients dont la maladie avait progressé après un traitement conventionnel par cellules CAR-T ciblant le CD19 (« CAR après CAR »). Toutes les réponses complètes étaient toujours en cours à la date de clôture des données ; aucune rechute n'a été observée et la réponse complète la plus longue en cours atteignait 35 mois, ce qui laisse entrevoir la possibilité d'une guérison.

Le PMB-CT01 s'est révélé remarquablement bien toléré, puisque tous les cas de syndrome de libération de cytokines et les deux cas signalés de syndrome de neurotoxicité associé aux cellules effectrices immunitaires se sont limités au grade 1.

Au vu de ces résultats prometteurs, l'essai de phase 1 s'est étendu d'un seul site clinique, situé à City of Hope, un organisme dédié à la recherche et au traitement du cancer, à plusieurs autres centres médicaux à travers les États-Unis. La publication indique également que le premier patient traité dans le cadre de la phase d'extension — qui présentait un lymphome à cellules B de haut grade de type triple-hit après une progression de la maladie suite à un traitement par cellules CAR-T ciblant le CD19 — a également obtenu une réponse complète lors de la première évaluation de la maladie.

« La publication de ces données, validées par un comité de relecture, dans The Lancet constitue une reconnaissance importante de cette nouvelle thérapie », déclare le Dr Larry W. Kwak, fondateur scientifique de PeproMene Bio. « En l'absence de toute récidive, nous estimons que le PMB-CT01 constitue une option révolutionnaire en matière de cellules CAR-T pour les cancers du sang, qui étaient jusqu'alors considérés comme incurables. Son profil d'innocuité exceptionnel pourrait également permettre une administration en ambulatoire — améliorant ainsi l'accès aux soins pour les patients défavorisés — tout en ouvrant de nouvelles perspectives pour le traitement des maladies auto-immunes dans lesquelles la déplétion des lymphocytes B a déjà fait ses preuves. »

« Ces premiers résultats sont encourageants, en particulier pour les patients dont la maladie a évolué après un traitement par lymphocytes T ciblant les marqueurs CD19 ou CD20 », déclare le Dr Stephen Forman, coauteur de l'article et directeur de l'Hematologic Malignancies Institute du City of Hope. « Le City of Hope continuera à soutenir cet essai en tant que centre de coordination et site de fabrication, en plus de se charger du recrutement des patients. »

En décembre 2024, l'Institute for Follicular Lymphoma Innovation (IFLI) s'est engagé à verser jusqu'à 11 millions de dollars pour soutenir le développement clinique du PMB-CT01 chez les patients atteints d'un lymphome folliculaire récidivant ou réfractaire. « Pour les patients chez qui le lymphome réapparaît après un traitement par cellules CAR-T ciblant le CD19, une nouvelle cible peut représenter une nouvelle chance. » « L'IFLI est fier de soutenir PeproMene Bio dans le développement de la thérapie par cellules CAR-T BAFF-R et se réjouit de ces premières réponses durables », déclare le Dr Mehrdad Mobasher, M.D., M.P.H., associé exécutif à l'Institute for Follicular Lymphoma Innovation.

Informations sur la publication

Titre : BAFF-R CAR T-cell therapy for relapsed or refractory B-cell lymphomas

Revue : The Lancet (Research Letter)

DOI : https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)01329-2/fulltext

À propos du PMB-CT01

Le PMB-CT01 est une thérapie autologue à base de cellules CAR-T, première de sa catégorie, ciblant le récepteur du facteur d'activation des lymphocytes B (BAFF-R), actuellement évaluée dans le cadre d'essais cliniques de phase I en cours pour le traitement des LNH de type B récidivants/réfractaires et des LAL de type B récidivantes/réfractaires. Le BAFF-R est exprimé presque exclusivement sur les cellules B et est essentiel pour la survie des cellules B, réduisant la probabilité d'échapper à la perte d'antigène. PeproMene Bio a obtenu de City of Hope une licence de propriété intellectuelle relative à PMB-CT01.

À propos de PeproMene Bio

PeproMene Bio, Inc. est une société de biotechnologie en phase clinique située à Irvine, en Californie, qui développe de nouvelles thérapies pour traiter les cancers et les affections immunitaires. Pour plus d'informations, veuillez contacter Hazel Cheng, Ph.D., COO de PeproMene Bio, Inc., à l'adresse [email protected], ou rendez-vous sur https://pepromenebio.com/.

Déclarations prospectives

Ce communiqué de presse contient des déclarations prospectives soumises à des risques et des incertitudes, y compris des risques liés au développement clinique, aux résultats réglementaires, au potentiel thérapeutique et à la commercialisation. PeproMene Bio ne s'engage pas à mettre à jour les déclarations prospectives, sauf si la loi l'exige.

Contact presse, IFLI

Laura DiCaprio, APR

McDougall Communications

[email protected]

Share this article

PeproMene Bio gibt die Veröffentlichung bahnbrechender Ergebnisse einer klinischen Phase-1-Studie in The Lancet bekannt, die tiefe und anhaltende vollständige Remissionen bei rezidivierten/refraktären B-Zell-Lymphomen belegen, auch nach vorherigem Versagen einer CD19-CAR-T-Zell-Therapie

News provided by

PeproMene Bio, Inc.; Institute for Follicular Lymphoma Innovation (IFLI)

Sep 08, 2026, 06:01 ET

IRVINE, Kalifornien, 8. September 2026 /PRNewswire/ -- PeproMene Bio, Inc. gab heute bekannt, dass in The Lancet, einer der weltweit führenden medizinischen Fachzeitschriften, die Ergebnisse seiner klinischen Phase-1-Studie zur Bewertung von PMB-CT01, der auf BAFF-R gerichteten CAR-T-Zell-Therapie des Unternehmens und ersten ihrer Klasse, bei Patienten mit rezidiviertem oder refraktärem B-Zell-Non-Hodgkin-Lymphom veröffentlicht wurden.

Die Veröffentlichung berichtet von anhaltenden vollständigen klinischen Remissionen sowie einem günstigeren Sicherheitsprofil im Vergleich zu zugelassenen CAR-T-Zell-Therapien. Sieben von neun behandelten Patienten (80 %) erreichten ein vollständiges Ansprechen (CR), darunter vier von sechs Patienten, bei denen nach einer konventionellen CD19-gerichteten CAR-T-Zell-Therapie eine Progression eingetreten war („CAR after CAR"). Zum Zeitpunkt des Datenstichtags hielten alle vollständigen Remissionen weiterhin an, ohne beobachtete Rückfälle, und die längste anhaltende vollständige Remission betrug 35 Monate, was auf die Wahrscheinlichkeit einer Heilung hindeutet.

PMB-CT01 erwies sich als bemerkenswert sicher, da alle Fälle des Zytokinfreisetzungssyndroms (CRS) und die beiden gemeldeten Fälle des Immuneffektorzell-assoziierten Neurotoxizitätssyndroms (ICANS) auf Grad 1 beschränkt waren.

Aufgrund dieser vielversprechenden Ergebnisse wurde die Phase-1-Studie von einem einzigen Studienzentrum bei City of Hope, einer Organisation für Krebsforschung und -behandlung, auf mehrere weitere medizinische Zentren in den Vereinigten Staaten ausgeweitet. In der Veröffentlichung wird zudem berichtet, dass der erste in der Erweiterungsphase behandelte Patient – bei dem ein hochgradiges Triple-Hit-B-Zell-Lymphom nach einer CD19-gerichteten CAR-T-Zell-Therapie fortgeschritten war – bei der ersten Krankheitsbeurteilung ebenfalls ein vollständiges Ansprechen erzielte.

„Die Veröffentlichung dieser von Fachkollegen begutachteten Daten in The Lancet stellt eine bedeutende Anerkennung dieser neuartigen Therapie dar", sagte Larry W. Kwak, M.D., Ph.D., wissenschaftlicher Gründer von PeproMene Bio. „Da keine Rückfälle aufgetreten sind, sind wir davon überzeugt, dass PMB-CT01 eine bahnbrechende CAR-T-Zell-Therapieoption für Blutkrebserkrankungen darstellt, die bislang als unheilbar galten. Sein herausragendes Sicherheitsprofil könnte zudem eine ambulante Verabreichung ermöglichen – und damit den Zugang für unterversorgte Patienten verbessern – sowie zugleich neue Möglichkeiten für die Behandlung von Autoimmunerkrankungen eröffnen, bei denen sich die B-Zell-Depletion bereits bewährt hat."

„Diese ersten Ergebnisse sind vielversprechend, insbesondere für Patienten, deren Erkrankung nach einer gegen CD19 oder CD20 gerichteten T-Zell-Therapie fortgeschritten ist", sagte Stephen Forman, M.D., Mitautor der Veröffentlichung und Direktor des Hematologic Malignancies Institute bei City of Hope. „City of Hope wird die Studie weiterhin als Koordinationszentrum und Produktionsstandort sowie bei der Patientenrekrutierung unterstützen."

Im Dezember 2024 stellte das Institute for Follicular Lymphoma Innovation (IFLI) bis zu 11 Millionen US-Dollar zur Unterstützung der klinischen Entwicklung von PMB-CT01 bei Patienten mit rezidiviertem oder refraktärem follikulärem Lymphom bereit. „Für Patienten, bei denen das Lymphom nach einer CD19-gerichteten CAR-T-Zell-Therapie wieder auftritt, kann ein neues Ziel eine neue Chance bedeuten. IFLI ist stolz darauf, PeproMene Bio bei der Weiterentwicklung der BAFF-R-CAR-T-Zell-Therapie zu unterstützen, und sieht das frühe und anhaltende Ansprechen als ermutigend an", sagte Mehrdad Mobasher, M.D., M.P.H., geschäftsführender Partner beim Institute for Follicular Lymphoma Innovation.

Angaben zur Veröffentlichung

Titel: BAFF-R-CAR-T-Zell-Therapie bei rezidivierten oder refraktären B-Zell-Lymphomen

Zeitschrift: The Lancet (Forschungsbrief)

DOI: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)01329-2/fulltext

Informationen zu PMB-CT01

PMB-CT01 ist eine autologe CAR-T-Zell-Therapie, die als erste ihrer Klasse auf den Rezeptor für den B-Zell-aktivierenden Faktor (BAFF-R) abzielt und derzeit in laufenden Phase-1-Studien bei rezidiviertem/refraktärem B-NHL sowie rezidivierter/refraktärer B-ALL untersucht wird. BAFF-R wird fast ausschließlich auf B-Zellen exprimiert und ist für das Überleben der B-Zellen unerlässlich, wodurch die Wahrscheinlichkeit eines Entkommens durch Antigenverlust verringert wird. PeproMene Bio hat von City of Hope geistiges Eigentum im Zusammenhang mit PMB-CT01 lizenziert.

Informationen zu PeproMene Bio

PeproMene Bio, Inc. ist ein Biotechnologieunternehmen in der klinischen Entwicklungsphase mit Sitz in Irvine, Kalifornien, das neuartige Therapien zur Behandlung von Krebserkrankungen und Immunerkrankungen entwickelt. Für weitere Informationen wenden Sie sich bitte per E-Mail an Hazel Cheng, Ph.D., Betriebsleiterin von PeproMene Bio, Inc.: [email protected] oder besuchen Sie https://pepromenebio.com/.

Zukunftsgerichtete Aussagen

Diese Pressemitteilung enthält zukunftsgerichtete Aussagen, die Risiken und Unsicherheiten unterliegen, darunter Risiken im Zusammenhang mit der klinischen Entwicklung, behördlichen Entscheidungen, dem therapeutischen Potenzial sowie der Vermarktung. PeproMene Bio übernimmt keine Verpflichtung, zukunftsgerichtete Aussagen zu aktualisieren, es sei denn, dies ist gesetzlich vorgeschrieben.

Medienkontakt, IFLI

Laura DiCaprio, APR

McDougall Communications

[email protected]

Share this article

Bulat Utemuratov Foundation Allocates 460 Million Tenge to Support Almaty Gasification Project

ALMATY, Kazakhstan, Sept. 8, 2026 /PRNewswire/ -- The Bulat Utemuratov Foundation announced a 460 million tenge (approx. US$1 million) allocation to support the gasification of private residential homes in Almaty. The initiative, implemented in partnership with the Almaty City Akimat (Mayor's Office), aims to develop urban infrastructure, improving living conditions and the city's air quality.

Under a newly signed memorandum, the Almaty City Akimat will inspect private residences, consult with residents on the connection process and provide comprehensive support for the transition to natural gas heating. Following this process, qualified contractors will carry out the necessary construction and installation work.

Darkhan Satybaldy, Akim (Mayor) of Almaty, emphasized: "We continue targeted work to connect private homes to the city's gas supply network. The requirements may vary in each case, which is why it is important to comprehensively support residents, from consultations to the actual connection, alongside technical work. The support of socially responsible businesses allows us to broaden this initiative."

The transition from coal to natural gas in private homes is a crucial step toward improving Almaty's air quality. During the heating season, the use of solid fuels in the private sector remains a major source of pollution.

Ainur Karbozova, CEO of the Bulat Utemuratov Foundation, noted: "It is important for us to support a project aimed at developing urban infrastructure and creating more comfortable conditions for the residents of Almaty. The gasification of the private sector will enable families who are not yet connected to the gas supply system to transition to a modern heating method. We are delighted to support this city initiative."

This gasification project builds on the Foundation's long-standing commitment to Almaty. Previous initiatives in the city include a comprehensive reconstruction of the Botanical Garden, modernization of the ventilation and air conditioning systems at the National Central Museum of the Republic of Kazakhstan, and the opening of one of the first Asyl Miras Autism Centers. During the COVID-19 pandemic, the Foundation also supported the local healthcare system by installing mobile PCR testing laboratories.

Share this article

Alocity combines Mercury's proven open access control foundation with its AI Operating System, giving integrators and customers a modern path to unify access, video, intercom, visitors, and AI without being locked into a closed ecosystem.

PEMBROKE PINES, Fla., Sept. 8, 2026 /PRNewswire/ -- Alocity, the AI Operating System for physical spaces, today announced support for Mercury Security's open access control platform, bringing together Mercury's proven controller infrastructure with Alocity's cloud-native access control, AI Video, Aimee AI operator, intercom, visitor management, and intelligent workflows.

The collaboration represents an important step forward for a physical security industry that has historically required customers to choose between proven infrastructure and the latest generation of cloud and AI software.

With Mercury as an open access control foundation, Alocity can deliver a modern software and AI experience while preserving the flexibility that security integrators and enterprise customers expect from an open architecture.

"Open infrastructure underneath. Intelligent software above it."

Modernizing Access Control Without Closing the Ecosystem

Access control infrastructure is designed to remain in buildings for many years. Controllers, readers, locks, cameras, and field wiring often outlive multiple generations of software.

Alocity believes modernization should not require customers to abandon those investments simply to gain access to modern cloud management, AI, mobile credentials, video intelligence, or automation.

Mercury's open architecture provides the infrastructure foundation for that strategy. Alocity adds the intelligence layer - connecting access control with AI-powered video, intercom, visitor management, workflows, and operational data through one cloud platform.

"Mercury represents what the physical security industry needs more of: open infrastructure and customer choice. We can combine that proven access control foundation with an entirely new generation of AI-driven software." - Marco Quintero, Founder and CEO, Alocity

From Access Control Software to an AI Operating System

The larger opportunity is not simply moving access control software to the cloud. Alocity is building an AI operating layer across the physical environment.

Through Aimee, Alocity's AI operator, authorized users can interact with access control, cameras, visitors, intercoms, and AI Video Agents using natural language. Instead of treating access control, video, and visitor management as separate applications, Alocity allows these systems to share context and operate together.

This creates a new model for physical security: systems that do more than record events - they understand what is happening and help teams respond.

What teams can ask Aimee

- "Show me everyone who entered the loading dock after 9 PM."

- "Was there anyone tailgating through the west entrance this morning?"

- "Find the vehicle associated with this access event."

- "If this door is forced open after hours, alert security and show the nearest cameras."

- "Generate an access and security report for all locations this week."

Open from the Door to the Camera

The Mercury relationship extends Alocity's broader open-platform strategy.

On the video side, Alocity AIVR works with existing IP cameras to add AI search, real-time detection, contextual reasoning, and AI Video Agents. On the access side, Mercury provides an open controller architecture capable of supporting a broad ecosystem of readers, credentials, locking hardware, and downstream devices.

Alocity connects these environments through one AI-driven Control Center. The result gives customers and integrators greater freedom to select the hardware that fits each project while standardizing the software, intelligence, and user experience across the organization.

Built for the Integrator Channel

For Alocity's security integration partners, Mercury support creates a new way to offer modernization without forcing customers into another proprietary hardware stack.

Partners can design new Mercury-based Alocity systems or help customers evolve existing Mercury environments toward modern cloud management, AI Video, and intelligent automation.

This allows integrators to lead with the customer's business problem - modernization, AI, operational efficiency, cybersecurity, video intelligence, or unified management - instead of beginning every conversation with hardware replacement.

A New Generation of Open Physical Security

Physical security is entering the same transformation that reshaped enterprise IT: infrastructure is becoming increasingly open while software and AI become the primary drivers of user experience, automation, and business value.

Alocity believes the future will not be won by forcing customers into another closed ecosystem. It will be built by connecting proven infrastructure with an intelligent software layer capable of understanding cameras, doors, people, vehicles, visitors, and physical events together.

Mercury provides an important foundation for that future. Alocity provides the intelligence layer above it. Together, they give integrators and customers a path toward a more open, modern, and AI-driven physical security architecture.

"Our partners already understand Mercury and why open architecture matters. Alocity gives them a new software and AI platform to bring to those conversations." - DJ Atkins, SVP, Channel Development

What this means

About Alocity

Alocity is the AI Operating System for physical spaces, bringing AI Video, access control, intercom, visitor management, and intelligent workflows together in one unified platform. Alocity's AIVR technology adds AI intelligence to existing IP cameras, while Aimee, the company's AI operator, enables security, facilities, and operations teams to search, understand, and operate their physical environments using natural language.

Alocity works through security integrators and channel partners to help organizations modernize physical security without forcing them into closed technology ecosystems.

Learn more: Read the full announcement.

Mercury and HID are trademarks of their respective owners. Mercury Security is a brand of HID. Product availability and supported Mercury hardware configurations are subject to Alocity and Mercury certification requirements.

Media Contact:

Sage Quiamno

[email protected] 

SOURCE Alocity

Share this article

Waterdrop Inc. Announces Second Quarter 2026 Unaudited Financial Results and a Cash Dividend

BEIJING, Sept. 8, 2026 /PRNewswire/ -- Waterdrop Inc. ("Waterdrop", the "Company" or "we") (NYSE: WDH), a leading technology platform dedicated to insurance and healthcare services with a positive social impact, today announced its unaudited financial results for the three and six months ended June 30, 2026 and a cash dividend.

Financial and Operational Highlights for the Second Quarter of 2026

- Strong Core Business Growth: Net operating revenue for the second quarter rose to RMB1,448.2 million (US$213.4 million), representing a robust year-over-year increase of 72.8%. Insurance-related income for the quarter reached RMB1,333.2 million (US$196.5 million), up 80.5% from the same period in 2025.

- Improved Operating Performance: In the second quarter of 2026, operating profit was RMB111.3 million (US$16.4 million), marking a 39.2% quarter-over-quarter increase and a 14.3% year-over-year increase.

- Broader Reach of Medical Crowdfunding: As of June 30, 2026, approximately 499 million individuals had cumulatively donated an aggregate of RMB74.7 billion to 3.82 million patients through Waterdrop Medical Crowdfunding.

- Continued Expansion in Patient Enrollment: As of June 30, 2026, the Company had facilitated the enrollment of 17,052 patients across 1,873 clinical trial programs through the E-Find Platform.

Mr. Peng Shen, Founder, Chairman, and Chief Executive Officer of Waterdrop, commented, "We are pleased to report another quarter of accelerating growth and strengthening profitability. Our AI initiatives continued to translate into tangible operating leverage.

We delivered solid results in insurance business, with an 80.5% year-over-year growth and a 16.4% quarter-over-quarter growth in insurance-related income. Continued refinement of our AI models improved conversion efficiency, leading to a 32.3% sequential increase in the number of new customers acquired. Expanding access to insurance protection remains our core product strategy. During the quarter, we introduced 'Rongyi Bao,' the market's first long-term critical illness insurance product that requires no health disclosure and offers five-year guaranteed renewability. Together with our deepening insights into evolving user needs, these efforts translated into premium growth, with long-term premiums up 33.4% quarter-over-quarter.

AI is becoming the foundational layer powering how we sell and serve. Our AI deployment continued to enhance service efficiency and operational quality across our insurance business. In this quarter, premiums facilitated by our 'AI Medical Insurance Expert' rose by 25.6% sequentially. Our 'KEYI.AI' underwriting assistant has processed more than 13,000 inquiries to date. The number of users served by 'AI Super Pre-Sales Assistant' climbed by nearly 50% sequentially.

Our AI-powered risk controls for Medical Crowdfunding resulted in marked improvement this quarter. As part of our risk review system, a new asset verification cross-references documents, medical records, and user-generated content to assess the possibility of undisclosed assets, such as property and vehicles, or unreported sources of income, and flags potential inconsistencies across the information reviewed.

Within our digital clinical trial business, the E-Find Platform delivered notably strong performance, especially in the chronic disease area. In the second quarter, we partnered with 255 pharmaceutical companies and contract research organizations and enrolled 1,540 patients. Revenue from digital clinical trial solutions was approximately RMB35.2 million, up 26.8% year-over-year.

Underscoring the commitment to shareholder returns, the board of directors of the Company (the "Board") has authorized the Company's sixth share repurchase program. Since the initial program launched in 2021, we had repurchased approximately 62.9 million ADSs for US$121.3 million as of August 31, 2026. We are also pleased to announce that, the Board has approved our sixth cash dividend of approximately US$10.8 million.

Waterdrop has always regarded technology as our core driver. With AI embedded across our platforms, we are well positioned to capture the growing demand in our existing businesses. Meanwhile, we continue to incubate new AI-driven business initiatives targeting global markets. We remain committed to delivering greater value for our shareholders in the years to come."

Financial Results for the Second Quarter of 2026

Operating revenue, net

Net operating revenue for the second quarter of 2026 reached RMB1,448.2 million (US$213.4 million), which represents an increase of 72.8% year-over-year from RMB838.0 million for the same period of 2025. On a quarter-over-quarter basis, net operating revenue increased by 16.6%.

- Insurance-related income includes insurance brokerage income and technical service income. Insurance brokerage income represents brokerage commissions earned from insurance companies. Technical service income is derived from providing analytics and intelligent recommendation service, risk assessment technical service and marketing services to insurance companies, insurance brokers, and insurance agencies. Reinforced by cumulative big data, we provide risk assessment technical services through an algorithm-driven verification system assessing risk by analyzing user profiles and medical histories, tagging risk levels for hierarchical management that help insurers refine their risk analysis capabilities since 2025. We leverage multi-dimensional consumer insights to deliver analytics and intelligent recommendation services, enabling policyholders to be matched with more suitable products and improving sales efficiency. Our insurance-related income amounted to RMB1,333.2 million (US$196.5 million) in the second quarter of 2026, representing an increase of 80.5% year-over-year from RMB738.6 million for the second quarter of 2025, driven mainly by enhanced risk assessment service capabilities and increased first-year premiums ("FYP") generated through our platform. Our technical service income amounted to RMB488.0 million (US$71.9 million) in the second quarter of 2026, compared with RMB160.9 million for the same quarter of 2025. On a quarter-over-quarter basis, insurance-related income increased by 16.4%, mainly due to the increase in insurance brokerage income.

- Crowdfunding service fees represent the service income earned when patients successfully withdraw the proceeds from their crowdfunding campaigns. Our role is to operate the Waterdrop Medical Crowdfunding platform to provide crowdfunding-related services through the internet, enabling patients with significant medical bills to seek help from caring hearts through technology (the "medical crowdfunding services"). Our medical crowdfunding services generally consist of providing technical and internet support, managing, reviewing and supervising the crowdfunding campaigns, providing comprehensive risk management and anti-fraud measures, and facilitating the collection and transfer of the funds. For the second quarter of 2026, we generated RMB63.6 million (US$9.4 million) in service fees, representing a decrease of 5.7% from RMB67.4 million for the second quarter of 2025. On a quarter-over-quarter basis, crowdfunding service fees increased by 4.7%.

- Digital clinical trial solution income represents the service income earned from our customers mainly including biopharmaceutical companies and leading biotechnology companies. We match qualified and suitable patients for enrollment in clinical trials for our customers and generate digital clinical trial solution revenue for successful matches and we typically charge our customers a fixed unit price per successful match. For the second quarter of 2026, our digital clinical trial solution income amounted to RMB35.2 million (US$5.2 million), representing an increase of 26.8% from RMB27.7 million in the same period of 2025. On a quarter-over-quarter basis, digital clinical trial solution income increased by 45.1%.

Operating costs and expenses

Operating costs and expenses increased by 80.5% year-over-year to RMB1,336.9 million (US$197.0 million) for the second quarter of 2026. On a quarter-over-quarter basis, operating costs and expenses increased by 15.0%.

- Operating costs increased by 29.0% year-over-year to RMB537.3 million (US$79.2 million) for the second quarter of 2026, as compared with RMB416.5 million for the second quarter of 2025, which was primarily driven by (i) an increase of RMB63.8 million in costs of referral and service fees, (ii) an increase of RMB21.4 million in short message service (SMS) costs for new user onboarding and authentication processes, (iii) an increase of RMB11.2 million in personnel costs, and (iv) an increase of RMB8.2 million in the costs for the digital clinical trial solution consultants team. On a quarter-over-quarter basis, operating costs increased by 10.4% from RMB486.8 million, primarily due to (i) an increase of RMB34.9 million in costs of referral and service fees, (ii) an increase of RMB11.2 million in personnel costs, and (iii) an increase of RMB8.3 million in the costs for the digital clinical trial solution consultants team, partially offset by (iv) a decrease of RMB12.7 million in the costs for SMS due to the decrease of volume of SMS sent during the quarter.

- Sales and marketing expenses increased by 220.7% year-over-year to RMB637.5 million (US$94.0 million) for the second quarter of 2026, as compared with RMB198.8 million for the same quarter of 2025. The increase was primarily due to (i) an increase of RMB415.0 million in marketing expenses for third-party traffic channels, and (ii) an increase of RMB21.8 million in marketing-related professional technical service fees. On a quarter-over-quarter basis, sales and marketing expenses increased by 17.8% from RMB541.1 million, primarily due to (i) an increase of RMB79.

MEXC Launches Opportunity Compass as 53.7% of Crypto Users Move Into Stocks but Knowledge Gaps Remain

Five-season program brings together industry partners to help crypto-native users better understand global markets, asset classes and emerging financial opportunities

MUTSAMUDU, Comoros, Sept. 8, 2026 /PRNewswire/ -- MEXC, a pioneer in 0-fee digital asset trading, today officially launched Opportunity Compass, a global markets education initiative aimed at advancing the market understanding as crypto and traditional finance become increasingly connected. Guided by the core message, "Know the Market, Know Your Opportunities," the initiative is designed to help crypto-native users build a more systematic understanding of traditional and crypto markets while bringing together perspectives from across the broader financial and digital asset ecosystem.

The initiative comes as crypto users increasingly look beyond digital assets. Recent research from MEXC and CoinGecko found that trading volumes for traditional financial assets on crypto exchanges reached $1.45 trillion in the first half of 2026, nearly 10 times the total recorded for all of 2025.

Key findings from MEXC's user survey include:

- 53.7% of respondents have already invested in stocks, showing that stock investing is becoming increasingly relevant to crypto-native users.

- Among users who have not used stock investment products, 43.1% cited insufficient investment knowledge as a key barrier.

- Among users who previously used stock products but stopped, 48.3% said limited investment knowledge was one of the reasons they discontinued participation.

- Among current stock investors, 44% said individual stock price movements influenced their participation, while 34% pointed to the AI boom as a key driver.

The findings suggest that access is expanding faster than understanding. As crypto-native users move across stocks, ETFs, commodities and digital assets, many are still developing the knowledge needed to understand market cycles, industry trends, asset behavior and investment risk. Greater access to financial opportunities therefore creates a growing need for more structured market education.

"Finding opportunities is important. What matters even more is having a systematic way to understand, evaluate and act on them," said Vugar Usi Zade, CEO of MEXC. "As financial markets become more connected and users gain exposure to a wider range of assets, they need more than access alone. Opportunity Compass is designed to help users understand what drives different markets, evaluate opportunities and risks, and ultimately build their own framework for navigating a more complex financial landscape."

Building Market Education with Industry Participants

Opportunity Compass is designed not only as an MEXC education program, but as a broader industry education initiative that brings together perspectives from across the evolving financial ecosystem. The group of participating partners includes xStocks by PAYWARD, Plume, Tether, Pyth, Optimism, CMT Digital and RootData, representing different parts of the digital asset and financial ecosystem.

With participation from industry partners alongside MEXC's educational content, Opportunity Compass aims to connect foundational market knowledge with broader industry perspectives, helping users better understand both established markets and the emerging models shaping the evolution of global finance.

Featuring five seasons and 30 episodes, Opportunity Compass takes users from understanding global markets and major asset classes to interpreting macroeconomic and industry trends, exploring emerging financial models and evaluating market opportunities. Rather than focusing on individual products or investment recommendations, the program aims to help users understand how markets work and what drives opportunities and risks.

From Seeing Opportunities to Understanding Markets

- Season 1: See the Global Opportunities. Understand the broader global financial market landscape and how different markets connect.

- Season 2: Understand Asset Value. Explore what gives stocks, gold, commodities, ETFs, Bitcoin and other assets value.

- Season 3: Decode Market Trends. Understand how interest rates, inflation, market cycles, earnings and industry trends such as AI and semiconductors shape markets.

- Season 4: Explore Emerging Opportunities. Explore tokenized assets, real-world assets, prediction markets and other emerging financial models at the intersection of crypto and traditional finance.

- Season 5: Become an Opportunity Explorer. Build an independent framework for understanding markets, evaluating opportunities and assessing risk.

Opportunity Compass will roll out progressively from September through December 2026, with new episodes released regularly across all five seasons through a dedicated Opportunity Compass education hub.

Extending MEXC's Infinite Opportunities philosophy into education, Opportunity Compass aims to help users not only discover more financial opportunities, but also develop the knowledge needed to understand and evaluate them more independently.

All Opportunity Compass content is intended for educational purposes only and does not constitute financial or investment advice.

About MEXC

Founded in 2018, MEXC is a leading global multi-asset trading platform built as your 0-fee gateway to infinite opportunities. Serving users across 170+ markets, MEXC provides simple and efficient access to crypto, stocks, tokenized assets, derivatives, and a growing range of TradFi-linked opportunities through one account and one gateway.

With 0 trading fees, deep liquidity, broad asset coverage, and a high-performance trading experience, MEXC is designed for retail users who want to discover earlier, act faster, and trade with fewer barriers. As crypto and traditional finance continue to converge, MEXC is committed to making global opportunities more accessible, helping users trade freely and MEXCmize every opportunity.

MEXC Official Website｜ X ｜ Telegram ｜How to Sign Up on MEXC

SOURCE MEXC

Share this article